Financial Information

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397

(SE) Redeye Investor Forum

26 October 2023

View our latest presentation!

Last week, Andreas represented Stayble Therapeutics at the Redeye Investor Forum. During the presentation, Andreas provided a detailed update on our latest developments and outlined the forthcoming plans and objectives.

For our Swedish listeners, view the presentation and learn more about our latest updates by following the link: https://lnkd.in/e36F7Agt

Back

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397